| Year |
Citation |
Score |
| 2024 |
Persenaire C, Babbs B, Yamamoto TM, Nebbia M, Jordan KR, Adams S, Lambert JR, Bitler BG. VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. Molecular Carcinogenesis. PMID 38558423 DOI: 10.1002/mc.23721 |
0.402 |
|
| 2024 |
Crump LS, Floyd JL, Kuo LW, Post MD, Bickerdike M, O'Neill K, Sompel K, Jordan KR, Corr BR, Marjon N, Woodruff ER, Richer JK, Bitler BG. Targeting tryptophan catabolism in ovarian cancer to attenuate macrophage infiltration and PD-L1 expression. Cancer Research Communications. 4: 822-33. PMID 38451784 DOI: 10.1158/2767-9764.CRC-23-0513 |
0.347 |
|
| 2024 |
Villagomez FR, Lang J, Webb P, Neville M, Woodruff ER, Bitler BG. Claudin-4 modulates autophagy via SLC1A5/LAT1 as a tolerance mechanism for genomic instability in ovarian cancer. Biorxiv : the Preprint Server For Biology. PMID 38293054 DOI: 10.1101/2024.01.18.576263 |
0.364 |
|
| 2023 |
Sottnik JL, Shackleford MT, Robinson SK, Villagomez FR, Bahnassy S, Oesterreich S, Hu J, Madak-Erdogan Z, Riggins RB, Corr BR, Cook LS, Treviño LS, Bitler BG, Sikora MJ. WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers. Cancer Research Communications. PMID 38112643 DOI: 10.1158/2767-9764.CRC-23-0275 |
0.328 |
|
| 2023 |
Bapat J, Yamamoto TM, Woodruff ER, Qamar L, Mikeska RG, Aird KM, Watson ZL, Brubaker LW, Bitler BG. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR. Cancer Gene Therapy. PMID 38030811 DOI: 10.1038/s41417-023-00703-1 |
0.405 |
|
| 2023 |
Callaway CS, Mouchantat LM, Bitler BG, Bonetto A. Mechanisms of Ovarian Cancer-Associated Cachexia. Endocrinology. 165. PMID 37980602 DOI: 10.1210/endocr/bqad176 |
0.343 |
|
| 2023 |
Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opinion On Therapeutic Targets. 1-11. PMID 37243607 DOI: 10.1080/14728222.2023.2218614 |
0.406 |
|
| 2023 |
Corr BR, Moroney MR, Woodruff E, Watson ZL, Jordan KR, Danhorn T, Bailey C, Wolsky RJ, Bitler BG. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in -mutated endometrial cancer. Biorxiv : the Preprint Server For Biology. PMID 37066339 DOI: 10.1101/2023.04.04.535570 |
0.423 |
|
| 2022 |
Neville MC, Webb PG, Baumgartner HK, Bitler BG. Claudin-4 localization in epithelial ovarian cancer. Heliyon. 8: e10862. PMID 36237976 DOI: 10.1016/j.heliyon.2022.e10862 |
0.312 |
|
| 2022 |
Holmberg R, Robinson M, Gilbert SF, Lujano-Olazaba O, Waters JA, Kogan E, Velasquez CLR, Stevenson D, Cruz LS, Alexander LJ, Lara J, Mu EM, Camillo JR, Bitler BG, Huxford T, et al. TWEAK-Fn14-RelB signaling cascade promotes stem cell-like features that contribute to post-chemotherapy ovarian cancer relapse. Molecular Cancer Research : McR. PMID 36214671 DOI: 10.1158/1541-7786.MCR-22-0486 |
0.413 |
|
| 2022 |
McMellen A, Yamamoto TM, Qamar L, Sanders BE, Nguyen LL, Ortiz Chavez D, Bapat J, Berning A, Post MD, Johnson J, Behbakht K, Nurmemmedov E, Chuong EB, Bitler BG. ATF6-mediated signaling contributes to PARP Inhibitor Resistance in Ovarian Cancer. Molecular Cancer Research : McR. PMID 36149636 DOI: 10.1158/1541-7786.MCR-22-0102 |
0.302 |
|
| 2022 |
Liu H, Lin J, Zhou W, Moses R, Dai Z, Kossenkov AV, Drapkin R, Bitler BG, Karakashev S, Zhang R. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. Cancer Immunology Research. OF1-OF11. PMID 35726891 DOI: 10.1158/2326-6066.CIR-22-0088 |
0.313 |
|
| 2022 |
Vu T, Wrobel J, Bitler BG, Schenk EL, Jordan KR, Ghosh D. SPF: A spatial and functional data analytic approach to cell imaging data. Plos Computational Biology. 18: e1009486. PMID 35704658 DOI: 10.1371/journal.pcbi.1009486 |
0.304 |
|
| 2022 |
Sanders BE, Yamamoto TM, McMellen A, Woodruff ER, Berning A, Post MD, Bitler BG. Targeting DUSP activity as a treatment for high grade serous ovarian carcinoma. Molecular Cancer Therapeutics. PMID 35587258 DOI: 10.1158/1535-7163.MCT-21-0682 |
0.398 |
|
| 2022 |
Yamamoto TM, Webb PG, Davis DM, Baumgartner HK, Woodruff ER, Guntupalli SR, Neville M, Behbakht K, Bitler BG. Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Molecular Cancer Therapeutics. 21: 647-657. PMID 35373300 DOI: 10.1158/1535-7163.MCT-21-0827 |
0.392 |
|
| 2021 |
Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Molecular Carcinogenesis. PMID 34038589 DOI: 10.1002/mc.23308 |
0.333 |
|
| 2020 |
Jordan K, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32928797 DOI: 10.1158/1078-0432.Ccr-20-1762 |
0.454 |
|
| 2020 |
McMellen A, Woodruff ER, Corr BR, Bitler BG, Moroney MR. Wnt Signaling in Gynecologic Malignancies. International Journal of Molecular Sciences. 21. PMID 32560059 DOI: 10.3390/Ijms21124272 |
0.385 |
|
| 2020 |
Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression. Molecular Cancer Research : McR. PMID 32198139 DOI: 10.1158/1541-7786.Mcr-19-1057 |
0.467 |
|
| 2020 |
Li J, Wang W, Zhang Y, Cieślik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, ... ... Bitler B, et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. The Journal of Clinical Investigation. PMID 32027624 DOI: 10.1172/Jci134402 |
0.458 |
|
| 2020 |
Webb P, Neville MC, Baumgartner-Wilson H, Post MD, Goodspeed A, Bitler BG. Abstract A30: Claudin-4-dependent mechanisms of high-grade serous ovarian cancer progression Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-A30 |
0.522 |
|
| 2020 |
Bitler BG, Sawyer B, Qamar L, Richer JK, Behbakht K, Schlaepfer IR. Abstract 5029: Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5029 |
0.383 |
|
| 2020 |
Moroney MR, Bitler BG, Corr BR. CTNNB1 Mutations are Associated with Decreased Disease-free Survival in a Low Risk Endometrial Cancer Group: An Analysis of the TCGA Database Gynecologic Oncology. 158. DOI: 10.1016/J.Ygyno.2020.04.004 |
0.36 |
|
| 2020 |
Sawyer B, Qamar L, Behbakht K, Schlaepfer I, Bitler B. Inhibition of Carnitine Palmitoyltransferase 1A Attenuates Ovarian Cancer Dissemination Gynecologic Oncology. 156: e3. DOI: 10.1016/J.Ygyno.2019.11.042 |
0.383 |
|
| 2019 |
Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clinical Epigenetics. 11: 165. PMID 31775874 DOI: 10.1186/S13148-019-0758-2 |
0.334 |
|
| 2019 |
Rao DM, Shackleford MT, Bordeaux EK, Sottnik JL, Ferguson RL, Yamamoto TM, Wellberg EA, Bitler BG, Sikora MJ. Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine O-acyltransferase or Wnt secretion. The Journal of Biological Chemistry. PMID 31740580 DOI: 10.1074/Jbc.Ra119.009615 |
0.399 |
|
| 2019 |
Smith LP, Bitler BG, Richer JK, Christenson JL. Tryptophan catabolism in epithelial ovarian carcinoma. Trends in Cancer Research. 14: 1-9. PMID 31736606 |
0.346 |
|
| 2019 |
Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, ... Bitler BG, et al. Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations. Molecular Cancer Therapeutics. PMID 31575654 DOI: 10.1158/1535-7163.Mct-17-0256 |
0.459 |
|
| 2019 |
Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Sawyer BT, Sullivan KD, Khanal S, Joshi M, Ferchaud-Roucher V, Smith H, Vanderlinden LA, Brubaker SW, Caino CM, Kim H, Espinosa JM, ... ... Bitler BG, et al. Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. Iscience. 19: 474-491. PMID 31437751 DOI: 10.1016/J.Isci.2019.07.049 |
0.401 |
|
| 2019 |
Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, Powell T, Jansson T, Wilson H. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Molecular and Cellular Biochemistry. PMID 31292831 DOI: 10.1007/S11010-019-03586-9 |
0.444 |
|
| 2019 |
Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, ... Bitler BG, et al. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Molecular Carcinogenesis. PMID 31219654 DOI: 10.1002/Mc.23064 |
0.414 |
|
| 2019 |
Dahl ES, Buj R, Leon KE, Newell JM, Imamura Y, Bitler BG, Snyder NW, Aird KM. Targeting IDH1 as a pro-senescent therapy in high-grade serous ovarian cancer. Molecular Cancer Research : McR. PMID 31110157 DOI: 10.1158/1541-7786.Mcr-18-1233 |
0.508 |
|
| 2019 |
Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Molecular Cancer Research : McR. PMID 30606772 DOI: 10.1158/1541-7786.Mcr-18-0451 |
0.486 |
|
| 2019 |
Watson ZL, Bitler BG. Type I Protein Arginine Methyltransferases Overexpression Promotes Transformation and Potentiates Her2/Neu-Driven Tumorigenesis. Cancer Research. 79: 3-4. PMID 30602621 DOI: 10.1158/0008-5472.Can-18-3552 |
0.417 |
|
| 2019 |
Wheeler LJ, Watson ZL, Qamar L, McMellen A, Yamamoto T, Behbakht K, Bitler BG. Abstract GMM-058: CBX2 IDENTIFIED AS DRIVER OF ANOIKIS ESCAPE AND DISSEMINATION IN HIGH GRADE SEROUS OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Gmm-058 |
0.512 |
|
| 2019 |
Wheeler L, Watson Z, Qamar L, Yamamoto T, Behbakht K, Bitler B. Chromobox 2 protein identified as driver of anoikis-escape and disease progression in high grade serous ovarian cancer Gynecologic Oncology. 154: e25-e26. DOI: 10.1016/J.Ygyno.2019.03.220 |
0.405 |
|
| 2019 |
Wheeler L, Watson Z, Yamamoto T, Sullivan K, Bitler B. Whole genome CRISPR/Cas9 screen identifies established and novel genes required for ovarian cancer dissemination Gynecologic Oncology. 153: e2. DOI: 10.1016/J.Ygyno.2019.03.108 |
0.366 |
|
| 2018 |
Fukumoto T, Zhang R, Bitler BG. Epigenetic inhibitors for the precision treatment of -mutant ovarian cancers: what are the next steps? Expert Review of Precision Medicine and Drug Development. 3: 233-236. PMID 30525111 DOI: 10.1080/23808993.2018.1503050 |
0.308 |
|
| 2018 |
Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 7: 92. PMID 30478317 DOI: 10.1038/s41389-018-0103-1 |
0.434 |
|
| 2018 |
Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nature Communications. 9: 4116. PMID 30297712 DOI: 10.1038/S41467-018-06656-6 |
0.396 |
|
| 2018 |
Gordon MA, Babbs B, Cochrane DR, Bitler B, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Molecular Carcinogenesis. PMID 30294913 DOI: 10.1002/Mc.22919 |
0.468 |
|
| 2018 |
Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Scientific Reports. 8: 14725. PMID 30282979 DOI: 10.1038/S41598-018-32885-2 |
0.406 |
|
| 2018 |
Fukumoto T, Park PH, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang TL, Shih IM, Conejo-Garcia JR, Bitler BG, Zhang R. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Reports. 22: 3393-3400. PMID 29590609 DOI: 10.1016/J.Celrep.2018.03.019 |
0.488 |
|
| 2018 |
Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nature Communications. 9: 631. PMID 29434212 DOI: 10.1038/S41467-018-03031-3 |
0.561 |
|
| 2018 |
Bitler B, Yamamoto T, Bales E, Watson Z, Behbakht K, Johnson J. Abstract B37: Prevention of epithelial ovarian cancer by eliciting P4/RIPK1-dependent necroptosis Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-B37 |
0.474 |
|
| 2018 |
Smith LP, Harrell LM, Christenson JL, Bitler B, Slansky J, Richer JK. Abstract 5137: Tryptophan catabolism in ovarian cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-5137 |
0.41 |
|
| 2017 |
Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Reports. 21: 3398-3405. PMID 29262321 DOI: 10.1016/J.Celrep.2017.11.095 |
0.507 |
|
| 2017 |
Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecologic Oncology. PMID 29037806 DOI: 10.1016/J.Ygyno.2017.10.003 |
0.41 |
|
| 2017 |
Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher Iii FJ, Zou W, Speicher DW, Huntsman DG, Conejo-Garcia JR, Cho KR, et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nature Cell Biology. PMID 28737768 DOI: 10.1038/Ncb3582 |
0.415 |
|
| 2017 |
Baumgartner HK, Rudolph MC, Ramanathan P, Burns V, Webb P, Bitler BG, Stein T, Kobayashi K, Neville MC. Developmental Expression of Claudins in the Mammary Gland. Journal of Mammary Gland Biology and Neoplasia. PMID 28455726 DOI: 10.1007/S10911-017-9379-6 |
0.308 |
|
| 2017 |
Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Bradner JE, Conejo-Garcia JR, Zhang R. Abstract AP31: TARGETING PD–L1/PD1 PATHWAY THROUGH BET PROTEIN INHIBITION IN EPITHELIAL OVARIAN CANCER Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ap31 |
0.371 |
|
| 2017 |
Bitler BG, Park PH, Hai Y, Aird KM, Wang Y, Huntsman DG, Cho KR, Christianson DW, Zhang R. Abstract AP25: INHIBITION OF HDAC ACTIVITY SELECTIVELY INHIBITS ARID1A–MUTATED OVARIAN CLEAR CELL CARCINOMA THROUGH A NOVEL P53 REGULATORY MECHANISM Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ap25 |
0.528 |
|
| 2016 |
Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, ... ... Bitler BG, et al. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Research. 76: 6320-6330. PMID 27803105 DOI: 10.1158/0008-5472.Can-16-0854 |
0.527 |
|
| 2016 |
Aird KM, Iwasaki O, Kossenkov AV, Tanizawa H, Fatkhutdinov N, Bitler BG, Le L, Alicea G, Yang TL, Johnson FB, Noma KI, Zhang R. HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci. The Journal of Cell Biology. PMID 27799366 DOI: 10.1083/Jcb.201608026 |
0.323 |
|
| 2016 |
Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW. The Primary Effect on the Proteome of ARID1A-Mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-Transcriptional Level. Molecular & Cellular Proteomics : McP. PMID 27654507 DOI: 10.1074/Mcp.M116.062539 |
0.425 |
|
| 2016 |
Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Reports. 16: 2829-2837. PMID 27626654 DOI: 10.1016/J.Celrep.2016.08.032 |
0.394 |
|
| 2016 |
Bitler BG, Aird KM, Zhang R. Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations. Molecular & Cellular Oncology. 3: e1032476. PMID 27308548 DOI: 10.1080/23723556.2015.1032476 |
0.354 |
|
| 2016 |
Bitler B, Shih I, Zhang R. Abstract B16: Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated ovarian cancers. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B16 |
0.463 |
|
| 2016 |
Bitler B, Garipov A, Shih IM, Zhang R. Abstract B30: Targeting EZH2 methyltransferase activity: A novel therapeutic approach to ARID1A-deficient cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B30 |
0.558 |
|
| 2015 |
Zhu H, Ren S, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y, Zhang R. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. Cell Reports. PMID 26527005 DOI: 10.1016/J.Celrep.2015.09.083 |
0.456 |
|
| 2015 |
Bitler BG, Fatkhutdinov N, Zhang R. Potential therapeutic targets in ARID1A-mutated cancers. Expert Opinion On Therapeutic Targets. 1-4. PMID 26125128 DOI: 10.1517/14728222.2015.1062879 |
0.479 |
|
| 2015 |
Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM, Conejo-Garcia JR, Speicher DW, Zhang R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine. 21: 231-8. PMID 25686104 DOI: 10.1038/Nm.3799 |
0.45 |
|
| 2013 |
Bitler BG, Fink LS, Wei Z, Peterson JR, Zhang R. A high-content screening assay for small-molecule modulators of oncogene-induced senescence. Journal of Biomolecular Screening. 18: 1054-61. PMID 23733845 DOI: 10.1177/1087057113491827 |
0.374 |
|
| 2013 |
Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Reports. 3: 1252-65. PMID 23562156 DOI: 10.1016/J.Celrep.2013.03.004 |
0.408 |
|
| 2013 |
Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S, Zhang R. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Molecular Cancer Research : McR. 11: 360-9. PMID 23360797 DOI: 10.1158/1541-7786.Mcr-12-0661 |
0.435 |
|
| 2013 |
Horm TM, Bitler BG, Broka DM, Louderbough J, Schroeder JA. Abstract A78: MUC1 drives c-Met-dependent migration and scattering Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-A78 |
0.76 |
|
| 2012 |
Horm TM, Bitler BG, Broka DM, Louderbough JM, Schroeder JA. MUC1 drives c-Met-dependent migration and scattering. Molecular Cancer Research : McR. 10: 1544-54. PMID 23193156 DOI: 10.1158/1541-7786.Mcr-12-0296 |
0.761 |
|
| 2012 |
Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prevention Research (Philadelphia, Pa.). 5: 484-91. PMID 22144423 DOI: 10.1158/1940-6207.Capr-11-0414 |
0.401 |
|
| 2011 |
Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, Yen TJ, Zhang R. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Developmental Cell. 21: 1077-91. PMID 22137763 DOI: 10.1016/J.Devcel.2011.10.010 |
0.314 |
|
| 2011 |
Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, Zhang R. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Research. 71: 6184-94. PMID 21816908 DOI: 10.1158/0008-5472.Can-11-1341 |
0.509 |
|
| 2011 |
Bitler BG, Nicodemus JP, Li H, Cai Q, Soring K, Birrer MJ, Connolly DC, Godwin AK, Cairns P, Wu H, Zhang R. Abstract 1230: Wnt5a-dependent induction of senescence suppresses epithelial ovarian cancer Cancer Research. 71: 1230-1230. DOI: 10.1158/1538-7445.Am2011-1230 |
0.505 |
|
| 2010 |
Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor Journal of Cell Science. 123: 1716-1723. PMID 20406885 DOI: 10.1242/Jcs.062661 |
0.741 |
|
| 2010 |
Bitler BG, Schroeder JA. Anti-cancer therapies that utilize cell penetrating peptides Recent Patents On Anti-Cancer Drug Discovery. 5: 99-108. PMID 19961434 DOI: 10.2174/157489210790936252 |
0.688 |
|
| 2010 |
Bitler BG, Goverdhan A, Schroeder J. Abstract 270: Modulation of EGFR localization and transcriptional activity Cancer Research. 70: 270-270. DOI: 10.1158/1538-7445.Am10-270 |
0.763 |
|
| 2007 |
Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor α-dependent cancer progression is modulated by Muc1 Cancer Research. 67: 6591-6598. PMID 17638868 DOI: 10.1158/0008-5472.Can-06-4518 |
0.695 |
|
| Show low-probability matches. |